| 姓名 | 職稱 | 持有股份 | 代表法人 |
|---|---|---|---|
| Xu,You-Shen | Chairman | 2.27% | |
| Chen,Bi-Rong | Director | 4.05% | |
| Li,Mei-Hui | Director | 21.13% | TAIWAN MASK CORPORATION |
| Xiao,Qin-Yi | Director | 21.13% | TAIWAN MASK CORPORATION |
| ZHONG JIA CONSULTANT CO., LTD. | Director | 0.00% | |
| Wu,Wei-Xiu | Director | 4.27% | SYNMOSA BIOPHARMA CORPORATION |
| Li,Min-Kui | Independent Director | 0.00% | |
| Li,Ru-Hong | Independent Director | 0.00% | |
| Huang,Ya-Hui | Independent Director | 0.00% |
Change Company Name to ADVAGENE BIOPHARMA CO., LTD.
2024/04/03
Change Company Name to YUHOU BIOTECHNOLOGY CO., LTD. (FORMER NAME: ZHANJUNYI CO., LTD.)
2022/08/19
Change Person in Charge to Xu,You-Shen
2022/07/28
Change Capital to 700,000,000
2021/09/08
Change Capital to 600,000,000
2018/10/30
Change Capital to 400,000,000
2017/05/10
Change Person in Charge to Chen,Bi-Rong
2016/03/25
Change Capital to 250,000,000
2016/01/21
Change Capital to 130,000,000
2014/10/15
Change Company Name to ADVAGENE BIOPHARMA CO., LTD.
2014/05/16
Change Capital to 120,000,000
2014/04/24
Change Person in Charge to Xu,Shan-Ke
2013/12/27
Change Person in Charge to Lai,Xing-Zhou
2013/08/01
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Operating income | - | - | - |
| Operating cost | - | - | - |
| Profit (loss) of initial recognition of biological asset and agricultural products | - | - | - |
| Profit (loss) on changes in fair value less costs to sell of biological asset for current period | - | - | - |
| Operating gross profit (loss) | - | - | - |
| Unrealized profit (loss) on sales of goods | - | - | - |
| Realized profit (loss) on sales of goods | - | - | - |
| Operating gross profit (loss), net | - | - | - |
| Operating expenses | 70,823 | 93,336 | 119,810 |
| Other gain (loss), net | - | - | - |
| Operating profit (loss) | -70,823 | -93,336 | -119,810 |
| Non-operating income and expenses | 1,402 | 1,226 | 1,433 |
| Net profit (loss) before tax | -69,421 | -92,110 | -118,377 |
| Income tax expense (benefits) | - | - | - |
| Net profit (loss) of ongoing business for the current period | -69,421 | -92,110 | -118,377 |
| Profit (loss) of closed units | - | - | - |
| Profit (loss) of non-jointly controlled equity before merger | - | - | - |
| Net profit (loss) for the current period | -69,421 | -92,110 | -118,377 |
| Other comprehensive profit (loss), net | - | - | - |
| Comprehensive net profit and loss of non-jointly controlled equity before merger | - | - | - |
| Total comprehensive profit and loss for the current period | -69,421 | -92,110 | -118,377 |
| Net profit (loss) attributable to owners of parent company | - | - | - |
| Net profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Net profit (loss) attributable to non-controlling interests | - | - | - |
| Comprehensive profit (loss) attributable to owners of parent company | - | - | - |
| Comprehensive profit (loss) form equity attributable to former owner of business combination under common control | - | - | - |
| Comprehensive profit (loss) attributable to non-controlling interests | - | - | - |
| Basic earnings per share (yuan) | -1 | -1 | -2 |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Net cash inflow (outflow) from operating activities | - | - | - |
| Net cash inflows (outflows) from investing activities | - | - | - |
| Net cash inflow (outflow) from financing activities | - | - | - |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | - | - | - |
| Increase (decrease) in cash and cash equivalents in the current period | - | - | - |
| Beginning balance of cash and cash equivalents | - | - | - |
| Ending balance of cash and cash equivalents | - | - | - |
| 項目 | 2024 | 2023 | 2022 |
|---|---|---|---|
| Current asset | 224,823 | 146,414 | 125,816 |
| Non-current asset | 7,385 | 1,520 | 15,022 |
| Total asset | 232,208 | 147,934 | 140,838 |
| Current liability | 7,107 | 7,972 | 8,423 |
| Non-current liability | 4,560 | 0 | 653 |
| Total liability | 11,667 | 7,972 | 9,076 |
| share capital | 593,800 | 533,800 | 493,490 |
| Equity - secruity token | - | - | - |
| capital reserve | 90,000 | 60,385 | 3,123 |
| retained earning | -463,259 | -454,223 | -364,851 |
| Other equity | - | - | - |
| Treasury stock | - | - | - |
| Total equity attributable to owners of parent company | - | - | - |
| Equity attributable to former owner of business combination under common control | - | - | - |
| Equity attributable to non-controlling interest before business merger under common control | - | - | - |
| Non-controlling interests | - | - | - |
| Total Equity | 220,541 | 139,962 | 131,762 |
| Share capital awaiting retirement (unit: share) | 0 | 0 | 0 |
| Issued shares of advance equity (unit: shares) | 0 | 0 | 0 |
| Treasury shares of the parent company held by the parent company and its subsidiaries (unit: share) | 0 | 0 | 0 |
| Net asset value per share | 3 | 2 | 2 |
